165 related articles for article (PubMed ID: 8391953)
1. Metalloproteinase inhibitors as therapeutics.
Gordon JL; Drummond AH; Galloway WA
Clin Exp Rheumatol; 1993; 11 Suppl 8():S91-4. PubMed ID: 8391953
[TBL] [Abstract][Full Text] [Related]
2. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation.
Jackson C; Nguyen M; Arkell J; Sambrook P
Inflamm Res; 2001 Apr; 50(4):183-6. PubMed ID: 11392606
[TBL] [Abstract][Full Text] [Related]
3. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis.
Itoh T; Matsuda H; Tanioka M; Kuwabara K; Itohara S; Suzuki R
J Immunol; 2002 Sep; 169(5):2643-7. PubMed ID: 12193736
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
5. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin-1alpha-induced cartilage oligomeric matrix protein degradation in bovine articular cartilage by matrix metalloproteinase inhibitors: potential role for matrix metalloproteinases in the generation of cartilage oligomeric matrix protein fragments in arthritic synovial fluid.
Ganu V; Goldberg R; Peppard J; Rediske J; Melton R; Hu SI; Wang W; Duvander C; Heinegård D
Arthritis Rheum; 1998 Dec; 41(12):2143-51. PubMed ID: 9870871
[TBL] [Abstract][Full Text] [Related]
7. Design and synthetic considerations of matrix metalloproteinase inhibitors.
Skotnicki JS; Zask A; Nelson FC; Albright JD; Levin JI
Ann N Y Acad Sci; 1999 Jun; 878():61-72. PubMed ID: 10415720
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases and their inhibitors in connective tissue remodeling.
Woessner JF
FASEB J; 1991 May; 5(8):2145-54. PubMed ID: 1850705
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and their inhibitors in tumour growth and invasion.
Kähäri VM; Saarialho-Kere U
Ann Med; 1999 Feb; 31(1):34-45. PubMed ID: 10219712
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium.
Kobayashi K; Arimura Y; Goto A; Okahara S; Endo T; Shinomura Y; Imai K
J Pathol; 2006 Jul; 209(3):376-83. PubMed ID: 16552705
[TBL] [Abstract][Full Text] [Related]
12. [Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in joint tissues of rapidly destructive coxarthropathy (RDC), analyzed by immunohistochemical study].
Matsumoto F; Uzuki M; Kaneko C; Rikimaru A; Kokubun S; Sawai T
Ryumachi; 1997 Oct; 37(5):688-95. PubMed ID: 9396371
[TBL] [Abstract][Full Text] [Related]
13. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts.
Migita K; Kawabe Y; Tominaga M; Origuchi T; Aoyagi T; Eguchi K
Lab Invest; 1998 May; 78(5):535-9. PubMed ID: 9605178
[TBL] [Abstract][Full Text] [Related]
14. [Matrix metalloproteinases and their biological functions].
Solov'eva NI
Bioorg Khim; 1998 Apr; 24(4):245-55. PubMed ID: 9612566
[TBL] [Abstract][Full Text] [Related]
15. Proteinases in rheumatoid arthritis.
Murphy G; Hembry RM
J Rheumatol Suppl; 1992 Jan; 32():61-4. PubMed ID: 1613735
[TBL] [Abstract][Full Text] [Related]
16. Rational design of tropoelastin peptide-based inhibitors of metalloproteinases.
Jensen SA; Andersen P; Vrhovski B; Weiss AS
Arch Biochem Biophys; 2003 Jan; 409(2):335-40. PubMed ID: 12504900
[TBL] [Abstract][Full Text] [Related]
17. Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies.
Itoh Y
Prog Mol Biol Transl Sci; 2017; 148():327-338. PubMed ID: 28662826
[TBL] [Abstract][Full Text] [Related]
18. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?
Murphy G; Nagase H
Nat Clin Pract Rheumatol; 2008 Mar; 4(3):128-35. PubMed ID: 18253109
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
Galis ZS; Sukhova GK; Lark MW; Libby P
J Clin Invest; 1994 Dec; 94(6):2493-503. PubMed ID: 7989608
[TBL] [Abstract][Full Text] [Related]
20. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor.
Borkakoti N; Winkler FK; Williams DH; D'Arcy A; Broadhurst MJ; Brown PA; Johnson WH; Murray EJ
Nat Struct Biol; 1994 Feb; 1(2):106-10. PubMed ID: 7656013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
